Abstract Library

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2270 Development of Pre-Clinical NEN Models – Limitations and Opportunities

Introduction: Pre-clinical research in neuroendocrine neoplasia (NEN) has long been impaired by the paucity of NET and NEC cell lines. Furthermore, established models have not been widely available or displayed unusual features (eg. p53 and ras mutations, high proliferation rate).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Schrader J

Authors: Schrader J, Benten D, Unrau L, Fahl M, Eggers C,

Keywords: cell line,

#2113 How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms

Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Fehrenbach U

Authors: Fehrenbach U, Fahlenkamp U, Prasad V, Pavel M, Geisel D,

Keywords: magnetic resonance, hepatocyte specific, liver specific, gadoxetate, gadoxetic acid, neuroendocrine, staging, shuttle, large bore, whole abdomen, pelvis, extrahepatic evaluation,

#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schrader J

Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,

Keywords: targeted therapies, mTOR,

#1867 Establishment of the First Well-Differentiated in Vivo Human Pancreatic Neuroendocrine Tumor Model

Introduction: The development of new therapeutic strategies for cancer patients relies on the in vitro and in vivo testing of novel substances in the pre-clinical setting. So far, this has not been possible for pancreatic neuroendocrine tumors (pNET) due to lack of suitable animal models resembling the disease course in human patients.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Schrader J, Unrau L, Stahl F, Eggers C, Fahl M,

Keywords: pNET, insulinoma, SSTR,